Pretreatment platelet count predicts survival outcome of patients with de novo non-M3 acute myeloid leukemia

PeerJ

article

Qianying Zhang¹  Kanchun Dai¹  Laixi Bi¹  Songfu Jiang¹  Yixiang Han²  Kang Yu¹  Shenghui Zhang¹ 

[1] Department of Hematology, The First Affiliated Hospital of Wenzhou Medical University;Central Laboratory, The First Affiliated Hospital of Wenzhou Medical University;Division of Clinical Research, The First Affiliated Hospital of Wenzhou Medical University

关键词: Acute myeloid leukemia;    Pretreatment platelet count;    Overall survival;    Disease-free survival;   

DOI  :  10.7717/peerj.4139

学科分类：社会科学、人文和艺术（综合）

来源: Inra

【 摘 要 】

BackgroundPretreatment platelet count has been reported as a potential tool to predict survival outcome in several solid tumors. However, the predictive value of pretreatment platelet count remains obscure in de novo acute myeloid leukemia (AML) excluding acute promyelocytic leukemia (M3).MethodsWe conducted a retrospective review of 209 patients with de novo non-M3 AML in our institute over a period of 8 years (2007–2015). Receiver operating characteristic (ROC) curve analysis was used to determine the optimal platelet (PLT) cutoff in patients. We analyzed the overall survival (OS) and disease free survival (DFS) using the log-rank test and Cox regression analysis.ResultsBy defining the platelet count 50 × 109/L and 120 × 109/L as two cut-off points, we categorized the patients into three groups: low (<50 × 109/L), medium (50–120 × 109120 × 109/L). On univariate analysis, patients with medium platelet count had longer OS and DFS than those with low or high platelet count. However, the multivariate analysis showed that only longer DFS was observed in patients with medium platelet count than those with low or high platelet count.ConclusionOur findings indicate that pretreatment platelet count has a predictive value for the prognosis of patients with non-M3 AML.

【 授权许可】

CC BY